IPS Biopharma is a biotech company developing a proprietary drug for use in the innovative cancer immunotherapy
inCVAX for the treatment of solid metastatic tumors. inCVAX belongs to a new class of therapeutics that utilize intratumoral
injections intended to induce customized immune activation against a patient’s own, unique cancer. In initial
clinical studies, several breast cancer patients experienced shrinkage of both local tumors and distant metastases
following inCVAX treatment. In some cases, this led to a complete, long-term response. Our first clinical trial in Switzerland
is a clear path forward to gain clinical evidence in additional indications.

ips-logo
ips-diagram-2
ips-diagram-1